Drug intelligence / Profile preview

BL1107

Development stage: Phase 2
Lead developer: Bausch & Lomb
Administration: Ophthalmic

Overview

BL1107 is an investigational ophthalmic drug being developed as an eye drop formulation for the treatment of primary open-angle glaucoma and ocular hypertension. It is currently being evaluated in a randomized, double-masked phase 2 clinical trial against timolol maleate 0.5% in adults, assessing safety and efficacy including visual field improvement and intraocular pressure (IOP) reduction. Detailed information regarding its precise mechanism of action, molecular structure, or active ingredient has not been publicly disclosed, as it remains in clinical development.[1][5][7]

Beyond the preview

Go deeper on BL1107.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on BL1107.

Explore the full profile